Klotho-Expressing Mesenchymal Stem Cells for Sustained Local Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases such as cancer, organ fibrosis, renal failure, age-related organ pathologies, arteriosclerosis, neurodegenerative diseases, and autoimmune diseases lack effective methods for local administration or continuous expression of Klotho protein, which is crucial for therapeutic benefits.
Innovation Solution
Genetically modified mesenchymal stem cells (MSCs) expressing a Klotho encoding region linked to a promoter or promoter/enhancer combination to enable local production and sustained release of Klotho protein at disease sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Klotho protein is administered systemically, then therapeutic benefits are achieved, but lack of localized continuous expression reduces treatment effectiveness
Solution Approach 1:
MSCs are pre-modified with Klotho encoding regions and promoters before administration, enabling them to autonomously produce and secrete Klotho protein continuously at the disease site after transplantation, eliminating the need for repeated systemic administrations
Solution Approach 2:
MSCs serve as living carriers that mediate between the administered Klotho encoding regions and the disease site, transporting and establishing continuous local production of Klotho protein directly at the target tissue
2Manufacturing precision
If Klotho is expressed locally at disease sites, then treatment precision is improved, but existing methods lack effective local administration capability
Solution Approach 1:
MSCs utilize their inherent homing capability to autonomously migrate to and engraft at disease sites after systemic administration, enabling self-directed localization without requiring complex targeting procedures or surgical intervention
Solution Approach 2:
The MSC-based system combines multiple functions: serving as a delivery vehicle, a factory for continuous protein production, and a self-targeting cell that locates disease sites autonomously, simplifying the overall treatment approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MSC-Klotho cells provide targeted delivery and sustained expression of Klotho, improving treatment outcomes for various diseases by enhancing cellular resistance to oxidative stress, regulating metabolic pathways, and promoting tissue repair and regeneration.
Implementation Method 1
enhancing cellular resistance to oxidative stress
Implementation Method 2
Klotho is a β-glucuronidase (EC number 3.2.1.31) capable of hydrolyzing steroid β-glucuronides
Data Source
AI summary
A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter/enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and/or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.